Generic placeholder image

Current Topics in Medicinal Chemistry


ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

PET Imaging of Multidrug Resistance in Tumors Using 18F-Fluoropaclitaxel

Author(s): Karen A. Kurdziel and Dale O. Kiesewetter

Volume 10, Issue 17, 2010

Page: [1792 - 1798] Pages: 7

DOI: 10.2174/156802610792928077

Price: $65


The failure of solid tumors to respond to chemotherapy is a complicated and clinically frustrating issue. The ability to predict which tumors will respond to treatment could reduce the human and monetary costs of cancer therapy by allowing pro-active selection of a chemotherapeutic to which the tumor does not express resistance. PET/CT imaging with a radiolabeled form of paclitaxel, F-18 fluoropaclitaxel (FPAC), may be able to predict the uptake of paclitaxel in solid tumors, and as a substrate of P-glycoprotein, it may also predict which tumors exhibit multidrug resistance (MDR), a phenotype in which tumors fail to respond to a wide variety of chemically unrelated chemotherapeutic agents. This article reviews the synthetic, preclinical and early human data obtained during the development phase of this promising new radiopharmaceutical.

Keywords: Drug development, Molecular Imaging, F-18 fluoropaclitaxel, Multidrug resistance, Paclitaxel, PET, Pgp, PET Imaging, 18F-Fluoropaclitaxel, P-glycoprotein, Tumor cells, chemotherapeutic agent, ABC (ATP Binding Cassette), Pgp expression, Cytochrome p450, Taxus brevifolia, Taxus baccata, Docetaxel, b-tubulin, Phenylisoserine moiety, [99mTc] sestamibi, [99mTc] tetrofosmin, tariquidar, XR9576, microPET, Pgp inhibitor, [18F]FPAC DMSO, Human breast tumor cell line, Standardized uptake value, MCF tumors, MIRDOSE, MDR modulator, Pgp modulation

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy